⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14869342 | 0.84 | GAA (0.30) | — | |
| SCHEMBL20799778 | 0.80 | — | — | |
| SCHEMBL14869253 | 0.75 | GAA (0.30) | — | |
| SCHEMBL20799779 | 0.75 | — | — | |
| SCHEMBL21984014 | 0.74 | — | — | |
| SCHEMBL14869229 | 0.73 | GAA (0.36) | — | |
| SCHEMBL20799903 | 0.70 | — | — | |
| SCHEMBL19165010 | 0.70 | GPR84 (0.36) | — | |
| SCHEMBL14869273 | 0.69 | DRD2 (0.37) | — | |
| SCHEMBL20799942 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |